CarboHyde

CarboHyde formulation team is growing! Onboarding of Tamas Kiss, PhD, welcome to our group, we look forward to our common journey with great excitement!

Cyclodextrins in Liposomes? Why not combine the two technologies? Cyclodextrin complexes have been widely used in pharmaceutical applications, but disadvantages such as the rapid clearance of cyclodextrins from the blood stream after in vivo administration or their replacement by other molecules in the biological medium with higher luminal affinity for cyclodextrins limit the application of cyclodextrins as drug carriers. Liposome-encapsulated hydrophobic drugs have low and unstable drug loading rates. Drug-in-CD-in-liposome (DCL), which encapsulate cyclodextrin inclusion complexes into liposomes, combine the advantages of both delivery systems, can effectively avoid the leakage and rapid release of lipophilic drugs in the lipid bilayer, and help to maintain the integrity of liposomes. Such cyclodextrin-liposome nanocomposites also have the possibility to deliver actives from ocular surface to the posterior segment of the eye: https://lnkd.in/dju-dKGF Here is a great review about the topic also: https://lnkd.in/dsHTX978

What do we go for in 2025? Walk the talk and continue the mission we began in 2022.

As we say in Hungary, here is to 2025, a year that will be better than 2024 and worse than 2026. Let's work towards that together!

CarboHyde's Cyclodextrin Masterclass II is coming soon! Our webinar, entitled “Cyclodextrins in drug delivery of biologics – current trends and future directions” is the 2nd episode in a series of webinars (CarboHyde’s Cyclodextrin Masterclass) that aims to provide educative content to cyclodextrin users and researcher on various applications. We will discuss developments 4 big areas: – monoclonal antibodies – gene therapy – vaccines – biotechnology January 30, 2025, 8:00 am – 8:45 am (EST) / 2:00 pm – 2:45 pm (CET) Learn more and register here: https://lnkd.in/d4WxnV-s #cyclodextrin #webinar #biologics

FDA Novel Drug Approvals of 2024 from the fascinating Chris De Savi Wrapping Up 2024: A Year of Relentless Drug Discovery Drug-hunting enthusiasts, here’s the complete roundup of 2024’s novel FDA-approved drugs! A total of 50 new molecular entities (NMEs) made the list—fewer than 2023’s 55 but more than 2022’s 38 approvals. Notable First-in-Class Approvals 💊 Revumenib: A menin inhibitor that disrupts menin-MLL protein interactions to halt cancer cell growth. Approved for relapsed or refractory acute leukemia with KMT2A translocation, it offers new hope for patients with resistant disease. 💉 Zanidatamab-hrii: A bispecific antibody targeting two HER2 receptor epitopes to enhance anti-tumor activity. It addresses HER2-positive biliary tract cancer, a rare and aggressive condition with few treatment options. 💊 Acoramidis: A transthyretin stabilizer that prevents protein misfolding and amyloid plaque deposition. Indicated for transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM), it improves outcomes for heart failure patients. 💉 Landiolol: An ultra-short-acting beta-1 adrenergic antagonist offering rapid, safe heart rate control for supraventricular tachycardia (SVT) with minimal risk of hypotension—advancing arrhythmia management. 💊 Crinecerfont: A corticotropin-releasing factor type 1 receptor antagonist that provides a novel approach for managing classic congenital adrenal hyperplasia (CAH). It reduces androgen production and restores hormonal balance. Therapeutic Focus Areas 40% of approvals target cancer, including lung cancer, leukemia, and gastric adenocarcinoma. 15% focus on cardiovascular conditions, like transthyretin-mediated amyloidosis. 10% address neurological disorders, such as congenital adrenal hyperplasia. 10% tackle infectious diseases, including resistant bacterial infections. The remaining 25% cover metabolic, genetic, and other diverse conditions. My Drug of the Year: Cobenfy Cobenfy stands out as a groundbreaking treatment for schizophrenia. Combining xanomeline, a muscarinic receptor agonist, with trospium chloride, a peripheral antagonist, it targets central nervous system receptors while minimizing side effects. Unlike dopamine-based treatments, this novel approach offers improved efficacy and fewer issues like weight gain and movement disorders. Schizophrenia, affecting 24 million people globally, has seen little innovation for decades. Cobenfy represents a new class of medication and a critical option for treatment-resistant patients, making it my standout drug of 2024. What’s your pick for drug of the year? Let’s celebrate the progress and look forward to 2025! #pharmaceuticals #medicine #healthcare

These guys can only write great reviews it seems. Interactions between #cyclodextrin and preservatives is a frequently asked question as CDs often reduce or even abolish the antimicrobial activities of commonly used pharmaceutical preservatives. The degree of inactivation depends on the CD complexation of the preservatives, which in turn depends on their chemical structure and physiochemical properties. In general, lipophilic preservatives are more likely to be inactivated; however, CDs are also known to inactivate highly water-soluble preservatives. Phatsawee Jansook, Hakon Hrafn Sigurdsson, Frédéric Pilotaz, Thorsteinn Loftsson

Growing and evolving year-by-year 🎉 🎉 🎉

Merry Christmas everyone!

The busy little elves at CarboHyde led by the Chief Charity Elf, Tündi have decided to make the Christmas of a family with 5 kids a bit happier. Let's do some good and kind today!